

## **ASX Release**

### **AdAlta Receives AU\$0.73m R&D Tax Incentive**

**The refund is based on AU\$1.6 million in eligible R&D spending used to advance the Company's lead i-body AD-114.**

**24th August 2016, Melbourne, Australia** – AdAlta Limited (ASX: 1AD), the biotechnology company specialising in the development of i-body protein-based therapeutics, has received a Research and Development Tax Incentive Refund of AUD\$0.73 million for the 2015/2016 financial year.

The refund is derived from AU\$1.6million of eligible R&D expenses incurred developing the lead i-body AD-114, which shows promise in treating fibrosis, notably idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies have limited efficacy and where there is a high-unmet medical need.

The R&D Tax Incentive is a program jointly administered by the Australian Taxation Office and AusIndustry, under which companies receive a 45% refundable tax offset of expenditures on eligible research and development activities.

Further information can be found at: [www.adalta.com.au](http://www.adalta.com.au)

#### **At the Company**

Sam Cobb  
Chief Executive Officer  
AdAlta Limited  
Tel: +61 (0) 3 9479 5159  
E: [s.cobb@adalta.com.au](mailto:s.cobb@adalta.com.au)